carbon monoxide has been researched along with alpha 1-Antitrypsin Deficiency in 11 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
alpha 1-Antitrypsin Deficiency: Deficiency of the protease inhibitor ALPHA 1-ANTITRYPSIN that manifests primarily as PULMONARY EMPHYSEMA and LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alpha(1)-AT-deficient and COPD patients had lower exhaled CO(2) than controls, although only alpha(1)-AT-deficient patients had higher exhaled O(2) than healthy controls." | 5.31 | Low levels of nitric oxide and carbon monoxide in alpha 1-antitrypsin deficiency. ( Dweik, RA; Erzurum, SC; Laskowski, D; Lupica, JA; Machado, RF; Stoller, JK; Zheng, S, 2002) |
| "Alpha(1)-AT-deficient and COPD patients had lower exhaled CO(2) than controls, although only alpha(1)-AT-deficient patients had higher exhaled O(2) than healthy controls." | 1.31 | Low levels of nitric oxide and carbon monoxide in alpha 1-antitrypsin deficiency. ( Dweik, RA; Erzurum, SC; Laskowski, D; Lupica, JA; Machado, RF; Stoller, JK; Zheng, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carpagnano, GE | 1 |
| Santacroce, R | 1 |
| Palmiotti, GA | 1 |
| Leccese, A | 1 |
| Giuffreda, E | 1 |
| Margaglione, M | 1 |
| Foschino Barbaro, MP | 1 |
| Aliberti, S | 1 |
| Lacedonia, D | 1 |
| Bernhard, N | 1 |
| Lepper, PM | 1 |
| Vogelmeier, C | 1 |
| Seibert, M | 1 |
| Wagenpfeil, S | 1 |
| Bals, R | 1 |
| Fähndrich, S | 1 |
| Westcott, A | 1 |
| Capaldi, DPI | 1 |
| Ouriadov, A | 1 |
| McCormack, DG | 1 |
| Parraga, G | 1 |
| Ward, H | 2 |
| Turner, AM | 1 |
| Stockley, RA | 3 |
| Soriano, JB | 1 |
| Miravitlles, M | 1 |
| Subramanian, DR | 1 |
| Edgar, R | 1 |
| Parr, DG | 2 |
| Machado, RF | 1 |
| Stoller, JK | 1 |
| Laskowski, D | 1 |
| Zheng, S | 1 |
| Lupica, JA | 1 |
| Dweik, RA | 1 |
| Erzurum, SC | 1 |
| Malerba, M | 2 |
| Radaeli, A | 2 |
| Ceriani, L | 2 |
| Tantucci, C | 2 |
| Grassi, V | 2 |
| Ricciardolo, F | 1 |
| Torregiani, C | 1 |
| Mori, E | 1 |
| Bontempelli, M | 1 |
| Stolk, J | 1 |
| Putter, H | 1 |
| Bakker, EM | 1 |
| Shaker, SB | 1 |
| Piitulainen, E | 1 |
| Russi, EW | 1 |
| Grebski, E | 1 |
| Dirksen, A | 1 |
| Reiber, JH | 1 |
| Stoel, BC | 1 |
| Silva, GE | 1 |
| Guerra, S | 1 |
| Keim, S | 1 |
| Barbee, RA | 1 |
| Sherrill, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized Trial With I.V. Prolastin® to Evaluate Frequency of Exacerbations and Progression of Emphysema by Means of Multi-slice CT Scans in Patients With Congenital Alpha-1-antitrypsin Deficiency.[NCT00263887] | Phase 2 | 77 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00263887)
Timeframe: 24 or 30 months
| Intervention | g/L (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change from Baseline | |
| Placebo | 45.477 | 41.354 | -4.124 |
| Prolastin (60 mg/kg Body Weight) | 47.980 | 45.085 | -2.895 |
1 trial available for carbon monoxide and alpha 1-Antitrypsin Deficiency
| Article | Year |
|---|---|
Airway hyperresponsiveness in a large group of subjects with alpha1-antitrypsin deficiency: a cross-sectional controlled study.
Topics: Adolescent; Adult; Aged; alpha 1-Antitrypsin Deficiency; Bronchial Hyperreactivity; Bronchial Provoc | 2003 |
10 other studies available for carbon monoxide and alpha 1-Antitrypsin Deficiency
| Article | Year |
|---|---|
A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Bronchiectasis; Carbon Monoxide; Female; Forced | 2017 |
Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Topics: Adult; Aged; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Carbon Monoxide; Disease Progressi | 2017 |
Hyperpolarized
Topics: alpha 1-Antitrypsin Deficiency; Carbon Monoxide; Diffusion; Diffusion Magnetic Resonance Imaging; Di | 2019 |
Spirometric and gas transfer discordance in a α1 -antitrypsin deficiency. patient characteristics and progression.
Topics: alpha 1-Antitrypsin Deficiency; Carbon Monoxide; Disease Progression; Female; Humans; Lung Volume Me | 2014 |
Your racing horses will help you to quit: a lesson for COPD and alpha1-antitrypsin deficiency research.
Topics: alpha 1-Antitrypsin Deficiency; Animals; Carbon Monoxide; Disease Progression; Forced Expiratory Vol | 2009 |
Prevalence and radiological outcomes of lung nodules in alpha 1-antitrypsin deficiency.
Topics: Adult; alpha 1-Antitrypsin Deficiency; C-Reactive Protein; Carbon Monoxide; Disease Progression; Fem | 2013 |
Low levels of nitric oxide and carbon monoxide in alpha 1-antitrypsin deficiency.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; alpha 1-Antitrypsin Deficiency; Bi | 2002 |
Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects.
Topics: Aged; alpha 1-Antitrypsin Deficiency; Bronchitis; Carbon Monoxide; Case-Control Studies; Female; For | 2006 |
Progression parameters for emphysema: a clinical investigation.
Topics: Absorptiometry, Photon; Adult; Aged; alpha 1-Antitrypsin Deficiency; Carbon Monoxide; Disease Progre | 2007 |
Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ alpha1-antitrypsin phenotype.
Topics: Adult; Aged; Aged, 80 and over; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Carbon Monoxide | 2008 |